Verona Pharma's Lung Disease Candidate Cuts COPD Exacerbations By 42%

Vandana Singh
1 min read
0
In this article:

  • Verona Pharma plc (NASDAQ: VRNA) has announced topline results from Phase 3 ENHANCE-2 of nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

  • The trial met its primary and secondary endpoints demonstrating improvements in lung function and significantly reduced the rate and risk of COPD exacerbations.

  • Subjects receiving ensifentrine demonstrated a 42% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks compared to those receiving placebo.

  • Ensifentrine was well tolerated with safety results similar to placebo.

  • "These data, along with results from our ongoing Phase 3 trial, ENHANCE-1, which are on track to be reported around the end of 2022, if similarly positive, are expected to support the submission of a New Drug Application to the US Food and Drug Administration in the first half of 2023," said David Zaccardelli, President & CEO.

  • Cash and cash equivalents at the end of Q2 were $111.5 million, sufficient to fund planned operating expenses and capital expenditure requirements through at least the end of 2023.

  • Price Action: VRNA shares are up 63.60% at $11.37 during the premarket session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories